Research topics
Microbiome articles covering gut bacteria, microbial changes, microbiota research, and IBD disease mechanisms.
Page 4 of 12 · 570 articles
The report explores NOD2/CARD15 variants in a Djiboutian IBD cohort and suggests higher variant frequencies in Crohn’s disease, which could point to population-specific genetic susceptibility. It also raises khat use as...
The paper links specific gut bacteria, inflammatory cytokines, and two microRNAs with UC activity, which could point toward new diagnostic biomarkers or targets for research into disease mechanisms.
Dietary macronutrients affect microbiota, barrier integrity, and mucosal immunity in ways that could alter IBD activity. Understanding these pathways could inform more targeted dietary strategies beyond generic...
Extracellular vesicle (EV) therapies are being explored as new ways to modulate immune responses and promote mucosal repair in IBD, which could eventually expand treatment options beyond current biologics and small...
Persistent diarrhea is a common, quality-of-life–limiting problem in ulcerative colitis; this review synthesizes how epithelial transport, barrier damage, immune signaling, mitochondria, and microbiota interact and...
If lymphatic dysfunction helps cause or sustain Crohn’s inflammation, it could explain some classic disease features (patchy, transmural inflammation and mesenteric changes) and point to new treatment approaches aimed at...
Preclinical data suggest blocking STAT3 with TTI-101 prevented colitis-associated colorectal tumors in a mouse model and altered tumor-related gene expression and the gut microbiome — findings that could guide future...
Microbial amino-acid metabolites may be active players in IBD biology and could become useful biomarkers or therapeutic targets. Understanding these metabolites helps explain links between the microbiome, immune...
The study targets TLR2 activation by bacterial curli, a mechanism linked to inflammation in IBD and other immune conditions. Engineering curli to inhibit TLR2 could become a strategy to create probiotics that reduce...
People with IBD may be concerned about environmental exposures that could influence inflammation or worsen disease. This review explains why micro- and nanoplastics are biologically plausible contributors but also why...
The study evaluates whether microbial networks differ between groups (including sexes) in IBD and other diseases using a rigorously tested method; that matters because robust methods are needed before microbiome patterns...
Researchers planned to study whether patterns in the gut microbiome correlate with clinical diagnoses (including Crohn’s and UC), which could inform future biomarker work. The study is suspended, so no results are...
Understanding how patient-derived epithelial cells respond to inflammation could reveal mechanisms of poor mucosal healing in IBD and identify targets or biomarkers to improve repair. Organoid models from patient tissue...
The study uses a mouse model of ulcerative colitis to test hemp seed oil and reports molecular and metabolic changes alongside reduced disease in the model. Patients and researchers may be interested because it explores...
Antibiotics can cause microbiome injury that increases risk of C. difficile and may worsen long-term health issues; identifying ways to protect the gut microbiome during antibiotic use could be especially relevant for...
The project targets a molecular regulator of tuft cells, which help control mucosal immune responses and have been linked to chronic gut inflammation such as ulcerative colitis. Discovering how OCA-T2 shapes tuft cell...
The paper identifies epothilone B as a repurposing candidate that may reduce neutrophil-driven inflammation and support epithelial healing in IBD models, a potential new strategy distinct from broad neutrophil...
Mucosal colonisation by adherent‑invasive E. coli has been implicated in Crohn’s disease for some patients; this study suggests FMT can change the mucosal microbiome and clear AIEC in a small pilot cohort, which could be...
Undernutrition and lean-mass loss are common and harmful in people with IBD. If dietary strategies can prevent weight and muscle loss and shift the gut microbiota toward SCFA producers, that could be relevant to...
The review suggests LJF contains compounds that may reduce intestinal inflammation, support gut barrier health, and influence microbiota—areas directly relevant to ulcerative colitis and colorectal cancer risk. However,...
NOD2 loss-of-function is a major genetic risk for Crohn’s disease, and this review highlights that gut microbes can modulate NOD2 signaling. That connection may help explain variation in disease risk and points to...
The paper links ileitis and changes in enterohepatic bile-acid composition to altered Th17 immune activity, suggesting bile-acid balance could influence inflammation in Crohn’s disease and might be a target for future...
The study presents a new inflammation-responsive oral delivery system designed to concentrate antioxidant and anti-inflammatory activity in the colon, which could—if translated safely to humans—offer a way to treat...
The exposome perspective emphasizes that many non-genetic, potentially modifiable environmental factors likely influence IBD risk. Understanding these factors could help guide prevention research and public-health...
The study links high levels of the bile acid DCA to microbiome and metabolite changes that correlate with intestinal inflammation in mice, suggesting a possible pathway connecting high‑fat diets to colitis risk.
The review suggests that specific Klebsiella pneumoniae strains could connect chronic IBD inflammation with rectal cancer risk, pointing to possible biomarker or prevention targets that may be relevant for people with...
Spatially resolved profiling could identify the specific cell neighborhoods and signaling circuits that drive disease in a person’s gut tissue, which may help predict who will respond to particular biologics or small...
Postoperative recurrence is common after intestinal resection for Crohn's disease, but clinicians currently lack reliable molecular biomarkers or validated models to predict who will relapse.
The paper connects a host microRNA (miR-29a) to gut microbiota bile-acid metabolism and an anti-inflammatory bile acid (LCA). If similar mechanisms apply in people, it could point to new biological targets or biomarkers...
The study introduces a colon-targeted EGCG delivery system that reduced inflammation and improved microbial and metabolic markers in a mouse model of UC, suggesting a potential new therapeutic approach worth further...
TGF-β1 is a central regulator implicated in inflammation control, development of fibrosis, and possible cancer progression in Crohn’s disease; advances in this area could inform future treatments or biomarker...
People with UC often use probiotics or microbiome-directed therapies alongside prescription drugs. Understanding probiotic–drug interactions could explain why individuals respond differently to IBD treatments and may...
Chronic antibiotic-refractory pouchitis is a common, impactful complication after ileal pouch-anal anastomosis that can worsen quality of life and increase the risk of pouch failure. Patients and clinicians need clearer...
This preclinical study connects an herbal medicine to changes in gut microbiota, inflammation, and intestinal barrier function in a mouse model of ulcerative colitis — findings that could inform future research on new...
A common heart drug, verapamil, reduced disease signs in a mouse model of colitis and altered inflammation and the gut microbiota — suggesting a possible avenue for future IBD research. These are preclinical results, so...
The review connects Western diet-driven metabolic shifts in the gut, immune cells, and microbiota to ulcerative colitis mechanisms and highlights metabolism-targeting therapies as a potential future avenue for treatment.
Researchers are studying how proteins from both the host and microbes in the gut relate to Crohn’s disease features. Findings could point to new noninvasive biomarkers or therapeutic strategies to correct dysbiosis,...
This trial tests whether adding nitazoxanide—an antiparasitic with reported antimicrobial and anti-inflammatory effects—can improve symptoms in people with mild-to-moderate ulcerative colitis. If effective, it could...
GPX and selenium-related pathways may be important to how oxidative stress, ferroptosis, and the microbiome contribute to IBD. Understanding these mechanisms could guide future therapies.
The paper suggests that the same herbal formula can produce different absorbed components and target interactions depending on oral versus colonic delivery, which could influence therapeutic effects in ulcerative colitis...
Macrophages are central regulators of intestinal inflammation and repair; understanding their diversity and how to modulate them could lead to new, more targeted treatments for Crohn's disease and ulcerative colitis.
Researchers found a candidate shared microbial signal across colorectal cancer, Crohn’s disease, and liver cirrhosis that points to redox-related microbial functions; this could guide future biomarker or experimental...
If validated, impaired oxalate handling could help explain why some people with IBD react differently to the same plant-rich diet and point to new dietary or microbiome-based interventions to reduce gut inflammation.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Materials today. Bio.
The study links a common dietary compound (oxalate) to worsened intestinal inflammation in IBD and identifies reduced gut oxalate-transport gene activity and microbiome differences as possible mechanisms—findings that...
The study shows that fecal (luminal) and mucosal microbiome and metabolite profiles capture different aspects of pediatric IBD—activity versus phenotype—so combined sampling may give a fuller picture for research and...
The study suggests a common plant compound (oxalate) may build up in the intestines of people with IBD because transporter proteins are reduced, potentially worsening inflammation. If confirmed, this could influence...
A single agent that both highlights inflamed colon tissue on MRI and delivers anti-inflammatory therapy could improve how ulcerative colitis is monitored and treated, reducing reliance on metal contrast agents.
